Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Cancer Medicine|November 22, 2020
Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trialAkira Ooki, Satoshi Morita, Akihito Tsuji, et al.
Nature Communications|July 13, 2024
Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudyHiroki Osumi, Eiji Shinozaki, Yoshiaki Nakamura, et al.
The Oncologist|August 10, 2022
The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final ResultsTetsuji Terazawa, Takeshi Kato, Masahiro Goto, et al.
Cancer Medicine|August 29, 2023
Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit studySatoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, et al.
Journal of Gastrointestinal Cancer|April 10, 2023
Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction CancerKei Muro, Kohei Shitara, Kensei Yamaguchi, et al.
International Journal of Clinical Oncology|April 30, 2022
Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational studyDaisuke Sakai, Takeshi Omori, Soichi Fumita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2024
Apalutamide and Goserelin for Androgen Receptor-Positive Salivary Gland Carcinoma: A Phase II Nonrandomized Clinical Trial, YATAGARASUYoshitaka Honma, Nobuya Monden, Keisuke Yamazaki, et al.
Cancer Immunology, Immunotherapy : CII|August 4, 2022
Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumabTatsuki Ikoma, Mototsugu Shimokawa, Toshihiko Matsumoto, et al.
Japanese Journal of Clinical Oncology|December 4, 2025
A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancerYoshiaki Nagatani, Naomi Kiyota, Tomoko Yamazaki, et al.
Future Oncology (London, England)|December 8, 2022
TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III BRAF V600E-mutated colorectal cancerShogen Boku, Hironaga Satake, Takashi Ohta, et al.
Pageof 12